Bulletin de la Bourse
InMed Pharmaceuticals Inc (IN) inscrit à la Bourse de Toronto
Issuer: InMed Pharmaceuticals Inc
Issuer: | InMed Pharmaceuticals Inc. (“InMed”) |
Security: | Common Shares (the “Shares”) |
Symbol(s): | IN |
Number of securities issued and outstanding: | 152,265,141 Shares |
Number of securities reserved for issuance: | 46,445,173 Shares |
Listing category: | Industrial, Non-Exempt Issuer |
Trading currency: | CDN$ |
Listing and posted for trading date: | March 26, 2018 (at the opening) |
Other market(s): | The Shares have been listed on the Canadian Securities Exchange (“CSE”) since May 21, 2014 and trade under the symbol “IN”. The Shares will be delisted from CSE on March 23, 2018 (at the close). |
Temporary market maker: | RBC Capital Markets |
Security ownership registration: | Certificated issue |
Investor relations: | Eric A. Adams CEO and President (604) 669-7207 ext. 212 Email: eadams@inmedpharma.com -and- Jeff Charpentier Chief Financial Officer (604) 669-7207 ext. 213 Email: jcharpentier@inmedpharma.com |
Incorporation: | Business Corporations Act (British Columbia) |
Fiscal year end: | June 30 |
Nature of business: | InMed is engaged in researching, developing, manufacturing and commercializing cannabinoid-based biopharmaceutical products to treat diseases with high unmet medical needs. |
Transfer agent and registrar: | Computershare Investor Services Inc. at its principal offices in Vancouver |
Dividends: | None anticipated in the foreseeable future. |
Sponsorship: | Canaccord Genuity Corp. |
TSX contact: | Julie K. Shin, Director, Listed Issuer Services, Toronto Stock Exchange. |